HD

331.51

+0.75%↑

TJX

162.24

+1.72%↑

LOW

236.79

+0.29%↑

ROST

221.92

+2.7%↑

AZO

3,414.46

+1.69%↑

HD

331.51

+0.75%↑

TJX

162.24

+1.72%↑

LOW

236.79

+0.29%↑

ROST

221.92

+2.7%↑

AZO

3,414.46

+1.69%↑

HD

331.51

+0.75%↑

TJX

162.24

+1.72%↑

LOW

236.79

+0.29%↑

ROST

221.92

+2.7%↑

AZO

3,414.46

+1.69%↑

HD

331.51

+0.75%↑

TJX

162.24

+1.72%↑

LOW

236.79

+0.29%↑

ROST

221.92

+2.7%↑

AZO

3,414.46

+1.69%↑

HD

331.51

+0.75%↑

TJX

162.24

+1.72%↑

LOW

236.79

+0.29%↑

ROST

221.92

+2.7%↑

AZO

3,414.46

+1.69%↑

Search

Medifast Inc

Atidarymo kaina

SektoriusVartotojų cikliškumas

10.15 0.69

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.96

Max

10.22

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-16M

-18M

Pardavimai

-14M

75M

P/E

Sektoriaus vid.

530

44.582

Pelno marža

-24.128

Darbuotojai

380

EBITDA

-5.1M

-4.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+20.12% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-13M

105M

Ankstesnė atidarymo kaina

9.46

Ankstesnė uždarymo kaina

10.15

Naujienos nuotaikos

By Acuity

70%

30%

301 / 338 reitingas Consumer cyclical

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Medifast Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai
Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai
Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

Medifast Inc Prognozė

Kainos tikslas

By TipRanks

20.12% į viršų

12 mėnesių prognozė

Vidutinis 12 USD  20.12%

Aukščiausias 12 USD

Žemiausias 12 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Medifast Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

0

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

12.35 / 12.98Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

301 / 338 reitingas Vartotojų cikliškumas

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Medifast Inc

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States and the Asia-Pacific. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups, as well as provides coaching support along with community, nutrition, and healthy habits, and helps people in their weight loss journey. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
help-icon Live chat